China Resources Pharmaceutical Group Management
Management criteria checks 3/4
China Resources Pharmaceutical Group's CEO is Xiaosong Bai, appointed in Jan 2022, has a tenure of 2.92 years. total yearly compensation is CN¥3.60M, comprised of 98.6% salary and 1.4% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth HK$1.08M. The average tenure of the management team and the board of directors is 2.9 years and 4.2 years respectively.
Key information
Xiaosong Bai
Chief executive officer
CN¥3.6m
Total compensation
| CEO salary percentage | 98.6% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.003% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Dec 19
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥4b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥4m | CN¥4m | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥4b |
Compensation vs Market: Xiaosong's total compensation ($USD493.55K) is about average for companies of similar size in the Hong Kong market ($USD471.21K).
Compensation vs Earnings: Xiaosong's compensation has increased by more than 20% in the past year.
CEO
Xiaosong Bai (53 yo)
2.9yrs
Tenure
CN¥3,601,000
Compensation
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.9yrs | CN¥3.60m | 0.0032% HK$ 1.1m | |
| VP & Executive Director | 3.3yrs | CN¥2.94m | no data | |
| CFO & Executive Director | 1.5yrs | no data | no data | |
| Chief Information Officer & VP | 11yrs | no data | no data | |
| Company Secretary | less than a year | no data | no data | |
| Vice President | no data | no data | no data | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | no data | no data |
2.9yrs
Average Tenure
53yo
Average Age
Experienced Management: 3320's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.9yrs | CN¥3.60m | 0.0032% HK$ 1.1m | |
| VP & Executive Director | 3.3yrs | CN¥2.94m | no data | |
| CFO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 8.5yrs | CN¥270.00k | no data | |
| Non-Executive Director | 2.9yrs | no data | no data | |
| Independent Non-Executive Director | 8.5yrs | CN¥270.00k | no data | |
| Independent Non-Executive Director | 8.5yrs | CN¥270.00k | no data | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 6yrs | no data | no data | |
| Non-Executive Director | 1.8yrs | no data | no data | |
| Independent Non-Executive Director | 7.3yrs | CN¥270.00k | no data | |
| Chairman | 5.2yrs | no data | 0.0048% HK$ 1.6m | |
| Non-Executive Director | less than a year | no data | no data |
4.2yrs
Average Tenure
57yo
Average Age
Experienced Board: 3320's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:24 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Resources Pharmaceutical Group Limited is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |